FDA Clearance Tracker · P990009-S013
FLOSEAL HEMOSTATIC MATRIX
Last checked: Nov 20, 2026Latest source record: Mar 10, 2005 (this decision)Source: openFDAMethods & limitations
Decided
Mar 10, 2005
Approved
Time to decision
843 days
Received Nov 18, 2002. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track
Device class
Class III
The decision
- FDA number
- P990009-S013
- Device name
- FLOSEAL HEMOSTATIC MATRIX
- Applicant
- Baxter Healthcare Corp
- Applicant location
- Round Lake, IL
- Received
- Nov 18, 2002
- Decided
- Mar 10, 2005
- Decision
- Approved
- Supplement type
- Normal 180 Day Track
- Reason for supplement
- Change Design/Components/Specifications/Material
- Original approval
- P990009
Device type
- Device class
- Class III
- Regulation
- 21 CFR 878.4490
- Specialty
- General & Plastic SurgeryWound Care
FDA's approval statement
As written in FDA's record.
APPROVAL FOR AN ALTERNATE KIT CONFIGURATION THAT CONTAINS A HUMAN THROMBIN COMPONENT. THE DEVICE, AS MODIFIED, WILL BE MARKETED UNDER THE TRADE NAME FLOSEAL HEMOSTATIC MATRIX AND IS INDICATED FOR USE IN SURGICAL PROCEDURES (OTHER THAN IN OPHTHALMIC) AS AN ADJUNCT TO HEMOSTASIS WHEN CONTROL OF BLEEDING BY LIGATURE OR CONVENTIONAL PROCEDURES IS INEFFECTIVE OR IMPRACTICAL.
Source documents
Other decisions for Baxter Healthcare Corp
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
- Helion Viewer Suite510(k)
K254265 · Decided May 27, 2026 · 148 days after receipt
Device type: System, Image Processing, Radiological (LLZ) · Radiology & Imaging
3 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.